Ischemic Stroke Pipeline Analysis: 30+ Key Companies Accelerating the Future of Stroke Therapeutics | DelveInsight

DelveInsight's "Ischemic Stroke Pipeline Insight 2026" report provides comprehensive global coverage of available, marketed, and pipeline ischemic stroke therapies in various stages of clinical development. Major pharmaceutical and biotechnology companies are actively working to advance the ischemic stroke pipeline landscape and improve future treatment opportunities for patients worldwide.

Key takeaways from the Ischemic Stroke Clinical Trial
Landscape Report
• DelveInsight's Ischemic Stroke pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for ischemic stroke treatment.
• Key Ischemic Stroke companies such as Athersys, SanBio, Biogen, Astrocyte Pharmaceuticals, Healios, DiaMedica Therapeutics, and others are evaluating novel therapeutic approaches for ischemic stroke management.
• Promising Ischemic Stroke pipeline therapies in various stages of development include MultiStem, SB623, BIIB093, AST-004, DM199, and others.

Request a sample and discover the recent advances in Ischemic Stroke treatment drugs https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Ischemic Stroke?
Ischemic Stroke is a neurological disorder caused by an obstruction in blood flow to the brain, leading to oxygen deprivation and brain tissue damage. It accounts for nearly 85% of all stroke cases globally and is associated with high mortality and long-term disability. Common symptoms include sudden weakness or numbness, difficulty speaking, loss of balance, blurred vision, and severe headache. Risk factors include hypertension, diabetes, atrial fibrillation, smoking, obesity, and cardiovascular diseases. Diagnosis involves neurological examination, brain imaging techniques such as CT and MRI scans, and vascular assessments. Current treatment strategies include thrombolytic therapy, mechanical thrombectomy, rehabilitation, and supportive care.

Emerging Ischemic Stroke Drug Profiles
MultiStem: Athersys
MultiStem is an investigational allogeneic stem cell therapy being developed for the treatment of ischemic stroke. The therapy is designed to modulate inflammation, protect damaged brain tissue, and support tissue repair and neurological recovery following stroke. MultiStem is administered intravenously and has demonstrated encouraging outcomes in improving functional recovery and reducing inflammatory responses in clinical studies.
SB623: SanBio
SB623 is a regenerative cell therapy derived from modified bone marrow mesenchymal stem cells intended to promote neurological recovery in patients with chronic motor deficits caused by ischemic stroke. The therapy is delivered through stereotactic implantation into the brain and aims to enhance neuronal repair and functional improvement.

Learn more about the novel and emerging Ischemic Stroke pipeline therapies https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Ischemic Stroke Clinical Trial Landscape
• In March 2026, SanBio announced continued progress in the clinical development of SB623 for chronic neurological motor deficits associated with ischemic stroke.
• In February 2026, Astrocyte Pharmaceuticals reported encouraging preclinical and early clinical findings for AST-004 in acute ischemic stroke patients.
• In January 2026, DiaMedica Therapeutics announced ongoing enrollment activities for its Phase II clinical trial evaluating DM199 in acute ischemic stroke.
• In December 2025, Biogen provided updates regarding the continued development of BIIB093 for large hemispheric infarction associated with ischemic stroke.
• In October 2025, Healios reported additional clinical insights related to MultiStem therapy in ischemic stroke patients aimed at improving neurological recovery outcomes.

Scope of the Ischemic Stroke Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Intracerebral
• Therapeutics Assessment By Molecule Type: Stem Cell Therapy, Small Molecule, Monoclonal Antibody, Peptide, Gene Therapy, Recombinant Protein
• Key Ischemic Stroke Companies: Athersys, SanBio, Biogen, Astrocyte Pharmaceuticals, Healios, DiaMedica Therapeutics, and others
• Key Ischemic Stroke Pipeline Therapies: MultiStem, SB623, BIIB093, AST-004, DM199, and others

Dive deep into rich insights for new drugs for Ischemic Stroke treatment, visit https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Ischemic Stroke Pipeline Report Introduction
2. Ischemic Stroke Pipeline Report Executive Summary
3. Ischemic Stroke Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Ischemic Stroke Pipeline Therapeutics
6. Ischemic Stroke Pipeline: Late Stage Products (Pre-registration)
7. Ischemic Stroke Pipeline: Late Stage Products (Phase III)
8. Ischemic Stroke Pipeline: Mid Stage Products (Phase II)
9. Ischemic Stroke Pipeline: Early Stage Products (Phase I)
10. Ischemic Stroke Pipeline Therapeutics Assessment
11. Inactive Products in the Ischemic Stroke Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Ischemic Stroke Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the Ischemic Stroke pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.